Ipamorelin vs GHRP-2: The Precision Tool and the Powerhouse

Put these two peptides side by side and they look like close relatives, and they are. Both are short synthetic chains that switch on the same receptor. Both came out of the same decades-long hunt for compounds that release growth hormone. Both have been through human studies. And yet one of them became an approved diagnostic drug in Japan, while the other was designed in Denmark precisely to avoid the side effects that come with its cousin’s raw power.

That tension, strength against selectivity, is what the whole Ipamorelin versus GHRP-2 comparison comes down to. This guide explains where each compound came from, what the key studies found, why one is stronger and the other cleaner, and how researchers decide which to use. Both are supplied by Crown Peptides for laboratory research use only.

Same Receptor, Same Family, Different Personalities

Ipamorelin and GHRP-2 both belong to a family called growth hormone releasing peptides, or GHRPs. They act on the growth hormone secretagogue receptor, better known today as the ghrelin receptor, which sits on growth hormone-producing cells in the pituitary gland and on neurons in the hypothalamus above it. When either peptide binds, those pituitary cells release a burst of growth hormone.

If that was the whole story, the two would be interchangeable. They are not, because the ghrelin receptor does more than release growth hormone. It is also tied into the body’s appetite system and, depending on the molecule activating it, into the stress hormone system. How a compound engages the receptor determines which of those effects come along for the ride. That is where the two part company.

The short version

GHRP-2 is the more potent growth hormone releaser, with a long clinical history and a notable appetite effect in human research. It also raises the stress hormones ACTH and cortisol, and to some extent prolactin. Ipamorelin releases growth hormone with a potency comparable to GHRP-6 but without significantly raising ACTH or cortisol, which is why it is described as the first selective growth hormone secretagogue.

The Discovery That Came Before the Receptor

The story of both compounds begins in the late 1970s with the American endocrinologist Cyril Bowers. He was modifying fragments of met-enkephalin, one of the body’s own opioid peptides, when he noticed that some of his synthetic molecules made the pituitary release growth hormone. They did not act like opioids, and they did not act on the receptor for growth hormone releasing hormone (GHRH). Something else was responding, and nobody knew what.

Over the following years, that line of work produced a series of increasingly potent peptides. GHRP-6, a six-amino-acid chain, arrived in the early 1980s. GHRP-1 and GHRP-2 followed. The receptor they acted on was finally cloned by a Merck team in 1996, and its natural hormone, ghrelin, was discovered by Japanese researchers in 1999. By then, GHRP-2 was already well into clinical development.

GHRP-2 becomes pralmorelin

GHRP-2 is also known by its drug name, pralmorelin, and by development codes such as KP-102. It was developed clinically in Japan, where it became a recognised diagnostic tool. A 2014 review of adult growth hormone deficiency by Fukuda and colleagues in Neurologia Medico-Chirurgica described the GHRP-2 stimulation test as an established method in Japan for diagnosing severe adult growth hormone deficiency, with a defined peak growth hormone cut-off (PMID: 25070016, PMC4533495).

That is a meaningful distinction. The test works because GHRP-2 is so reliably potent: give it to a person with a healthy pituitary and a large growth hormone response follows. A poor response points to a pituitary that cannot release growth hormone properly. Researchers in Japan have since explored GHRP-2 testing in other pituitary conditions too, including a 2018 study in Endocrine Journal on thyrotropin-producing pituitary adenomas.

How GHRP-2 behaves in the lab

The Japanese developer of pralmorelin published a detailed pharmacological profile of the compound, under its code name KP-102, in Arzneimittelforschung in 2004 (PMID: 15646370). Several findings help explain why GHRP-2 is so dependable.

It shrugs off the somatostatin brake

In conscious rats, GHRP-2 released growth hormone more potently than injected GHRH. Under anaesthesia, which lowers the body’s own somatostatin, the two became roughly equal. In conscious dogs, GHRP-2 still released growth hormone while GHRH failed to raise it at all. The authors concluded that GHRP-2’s effect was less sensitive to suppression by somatostatin, the body’s natural brake on growth hormone. That resilience is exactly what makes it useful as a diagnostic stimulus.

It needs the whole system to work at full strength

GHRP-2 had no effect in rats whose pituitary had been removed, confirming the pituitary as its target. In rats whose connection between hypothalamus and pituitary had been damaged, it still worked but released less growth hormone, showing that its full effect depends partly on the body’s own GHRH. In pituitary cells in a dish, it stimulated growth hormone directly, though more weakly than GHRH. In other words, GHRP-2 works best as part of a team, amplifying the brain’s own growth hormone signal.

A slight stress hormone effect, and a growth effect

The same study found GHRP-2 stimulated ACTH and corticosterone, the rat equivalent of cortisol, but not prolactin, and that three weeks of administration accelerated growth in rats. The authors described its growth hormone activity as specific apart from slight ACTH secretion, which fits neatly with the Novo Nordisk comparison.

A diagnostic tool beyond growth hormone

GHRP-2’s reliability has made it useful for more than growth hormone testing. In 2018, Kageyama and colleagues in Endocrine Journal explored whether it could help identify thyrotropin-producing pituitary adenomas, rare tumours that cause an overactive thyroid (PMID: 29973439). In healthy people GHRP-2 does not raise TSH, but in two of five patients with these tumours it produced a significant TSH response. It is a small study, but it shows how a well-characterised peptide can become a probe for pituitary biology in unexpected ways.

Ipamorelin: the Danish answer

While GHRP-2 was heading towards the clinic, chemists at Novo Nordisk in Denmark were working on a different goal. The GHRPs of the time were powerful, but they were not clean. They raised ACTH and cortisol along with growth hormone, and some raised prolactin. The Novo Nordisk team wanted a molecule that released growth hormone and nothing else.

Working systematically through compounds derived from GHRP-1, they removed its central two amino acids and modified the rest. The result was a five-building-block peptide they named Ipamorelin, introduced in 1998 in a paper whose title made its ambition plain: “Ipamorelin, the first selective growth hormone secretagogue.”

The Study That Compared Them Head to Head

That 1998 paper, published in the European Journal of Endocrinology by Raun and colleagues, is the single most useful source for this comparison, because it tested Ipamorelin against GHRP-2 and GHRP-6 directly (PMID: 9849822).

Potency

In rat pituitary cells grown in the laboratory, Ipamorelin released growth hormone with potency and efficacy similar to GHRP-6. In anaesthetised rats, it again matched GHRP-6. In conscious pigs, the researchers could compare all three. GHRP-2 was the most potent of the group: it took the smallest amount to produce half of its maximum growth hormone response. Ipamorelin and GHRP-6 needed more. Interestingly, though, GHRP-2’s maximum growth hormone response in pigs was somewhat lower than that of Ipamorelin or GHRP-6. In plain terms, GHRP-2 got going with less, while Ipamorelin reached a comparable or higher ceiling.

Selectivity

Then came the finding that defined Ipamorelin. None of the three compounds affected FSH, LH, prolactin or TSH in the pigs. But GHRP-6 and GHRP-2 both raised ACTH and cortisol. Ipamorelin did not. Its effect on those stress hormones was not significantly different from that of GHRH itself, even at amounts more than 200 times higher than those needed for growth hormone release. The authors concluded that Ipamorelin was the first GHRP-receptor agonist with a selectivity for growth hormone release similar to GHRH.

That pair of results, GHRP-2 more potent and Ipamorelin more selective, is the heart of every comparison between the two that has followed.

What GHRP-2 Research Has Shown in People

GHRP-2’s long clinical history means there is more human research on it than on most research peptides. Two findings stand out.

A reliable diagnostic signal

As described above, GHRP-2 has become a standard stimulation test in Japan for adult growth hormone deficiency. Its value in that role rests on its consistency: in people with a healthy pituitary, it reliably produces a large growth hormone release.

A clear appetite effect

In 2005, Laferrère, Bowers and colleagues published a small but striking study in the Journal of Clinical Endocrinology and Metabolism (PMID: 15699539, PMC2824650). Seven lean, healthy men received an infusion of GHRP-2 or saline, then sat down to a buffet meal and ate as much as they wanted. With GHRP-2, they ate 35.9% more, and every single participant increased their intake. The type of food chosen did not change, and growth hormone levels rose substantially as expected. The authors described GHRP-2 as a valuable tool for investigating ghrelin’s effects on eating behaviour in humans.

That study showed, for the first time in people, that GHRP-2 mimics ghrelin’s appetite effect as well as its growth hormone effect. For researchers, it makes GHRP-2 useful in two quite different fields: growth hormone physiology and the biology of hunger.

What Ipamorelin Research Has Shown

Ipamorelin’s research profile is built around its selectivity, and it has been explored across bone, muscle and the gut.

Bone growth and bone mineral

A 1999 Novo Nordisk study in Growth Hormone and IGF Research showed that Ipamorelin increased the longitudinal growth rate of the tibia in rats in a dose-dependent way (PMID: 10373343). A 2000 study from Gothenburg found that Ipamorelin, like GHRP-6 and growth hormone itself, increased bone mineral content in young adult female rats over 12 weeks, through increased bone size.

Protecting muscle and bone

A 2001 study from Aarhus University found that in rats given a high-dose glucocorticoid, adding Ipamorelin significantly increased calf muscle strength and produced a four-fold higher rate of bone formation compared with the glucocorticoid alone (PMID: 11735244).

Human pharmacokinetics

In healthy volunteers, a 1999 study in Pharmaceutical Research found Ipamorelin had a terminal half-life of about two hours and produced a single, clean pulse of growth hormone peaking around 40 minutes after infusion (PMID: 10496658). That neat, natural-looking pulse is part of why it is regarded as such a physiological research tool.

For the full Ipamorelin story, including its gut motility research and anti-doping metabolism studies, see our Ipamorelin research guide.

What the Wider Research on Growth Hormone Secretagogues Suggests

Ipamorelin and GHRP-2 sit within a larger class of compounds that includes GHRP-6, hexarelin and the oral small molecule ibutamoren. A 2018 review in Sexual Medicine Reviews by Sigalos and Pastuszak at Baylor College of Medicine surveyed the human research across the whole class (PMID: 28400207, PMC5632578).

The review highlighted one of the most attractive features of secretagogues as research tools: they promote pulsatile growth hormone release that remains subject to the body’s negative feedback, which can prevent growth hormone rising to excessive levels. Across the studies reviewed, secretagogues were reported to potentially improve growth velocity in children, stimulate appetite, improve lean mass in wasting states and obesity, decrease bone turnover, increase fat-free mass and improve sleep, and were generally well tolerated. The authors noted a signal of reduced insulin sensitivity to watch in future work, and called for longer, rigorously controlled studies. For researchers, that combination of broad promise and open questions is exactly what makes the class so active.

Ipamorelin vs GHRP-2: Side by Side

With the research laid out, the differences become easy to state.

Potency

GHRP-2 is the more potent of the two, needing less to trigger a growth hormone response. That is part of why it works so well as a diagnostic agent.

Selectivity

Ipamorelin is the more selective. In the original comparison it did not raise ACTH or cortisol, while GHRP-2 did. For any experiment where stress hormone changes would muddy the data, that matters.

Appetite

GHRP-2 has a well-documented appetite effect in humans. Ipamorelin still acts at the ghrelin receptor, and animal research has shown it can increase food intake in some settings, but its appetite profile is generally described as less prominent.

Size and structure

GHRP-2 is a hexapeptide, six building blocks long. Ipamorelin is a pentapeptide, five building blocks long. Both use unusual, non-standard amino acids to resist breakdown and fit the receptor.

Clinical history

GHRP-2, as pralmorelin, is an established diagnostic agent in Japan and has a larger body of human research. Ipamorelin reached phase 2 clinical trials, for postoperative ileus, and has a smaller but very precise body of pharmacological data.

Which Fits Your Research Question?

Autocomplete data shows people asking “which GHRP is best” and “Ipamorelin or GHRP-2?”. In research, the answer depends on what you are trying to measure.

Choose GHRP-2 when potency is the point

GHRP-2 is the stronger tool when you want a maximal, reliable growth hormone response, when you are working with established stimulation-test models, or when you want to study the appetite side of ghrelin receptor biology. Its human appetite data make it one of the best-characterised compounds for studying ghrelin-like effects on eating behaviour.

Choose Ipamorelin when cleanliness is the point

Ipamorelin is the better tool when you want growth hormone release without changes in ACTH and cortisol confounding the results, when you are studying the growth hormone axis in isolation, or when you want a neat pulse that closely resembles natural release.

Or use both as a pair

Because they share a receptor but differ in selectivity, running the same experiment with each can be revealing. Any effect that appears with GHRP-2 but not Ipamorelin may point towards the stress hormone or appetite pathways rather than growth hormone itself.

The Technical Breakdown: Two Structures, Two Outcomes

This section goes into the chemistry for readers who want it. The comparison above stands on its own.

The sequences

GHRP-2 is usually written D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2. Ipamorelin is written Aib-His-D-2-Nal-D-Phe-Lys-NH2. Both end in an amidated lysine, and both contain D-2-naphthylalanine and D-phenylalanine, bulky aromatic building blocks in their mirror-image D form.

What the shared parts do

The D-amino acids resist the enzymes that normally break down peptides, which are built to recognise the natural L forms. The bulky aromatic side chains of naphthylalanine and phenylalanine are thought to be key to fitting the ghrelin receptor’s binding pocket. The amidated end protects against enzymes that chew peptides from the tail.

What the differences do

GHRP-2 contains an alanine-tryptophan pair in its middle. Ipamorelin, derived from a series of compounds lacking the central Ala-Trp dipeptide of GHRP-1, does not. Instead, it begins with Aib (alpha-aminoisobutyric acid), a building block with two methyl groups that restricts how the chain can bend, followed by histidine. Those changes shift how the molecule sits in the receptor, and they are thought to underlie Ipamorelin’s selectivity, although the precise structural explanation is still an active research question.

Biased signalling

One increasingly popular way to explain why two molecules acting on the same receptor can have different effects is biased agonism. A receptor such as GHS-R1a can couple to more than one internal signalling pathway. Different molecules can stabilise slightly different receptor shapes that favour one pathway over another. GHRP-2 and Ipamorelin may be a classic example: both drive the growth hormone release signal, but they may engage the pathways linked to stress hormone release to different extents.

Where each acts

Both act at the pituitary to release growth hormone directly, and at the hypothalamus to increase GHRH release and reduce somatostatin, the brake on growth hormone. The ACTH and cortisol effects of GHRP-2 are thought to involve the hypothalamic-pituitary-adrenal axis, which Ipamorelin appears not to engage to a meaningful degree.

Why Short Peptides Need Careful Verification

Five and six building blocks sound simple to make. They are, relatively, but short peptides with unusual amino acids bring their own quality challenges.

First, stereochemistry matters. Several building blocks in each molecule must be D-amino acids. A version made with an L-amino acid in the wrong place would have exactly the same mass, so mass spectrometry alone could not tell them apart, yet it could behave quite differently. A clean HPLC profile and reliable synthesis are essential.

Second, these particular peptides have a documented history of lookalikes. In 2018, anti-doping scientists in Cologne reported black market products containing glycine-extended versions of GHRP-2, GHRP-6 and Ipamorelin, each with a single extra amino acid at the front (PMID: 29864719). Only mass spectrometry caught the difference. Our guide to peptide testing in the UK explains exactly how.

The Crown Peptides standard

Every batch of Ipamorelin and GHRP-2 supplied by Crown Peptides comes with a batch-specific certificate of analysis showing HPLC purity and mass spectrometry identity confirmation. Lot numbers on certificates match those on vial labels. Published certificates are on our Lab Reports page, and our guide to reading a certificate of analysis explains each figure.

Storage and handling

Both are supplied as lyophilised powders and should be kept cold, dry and away from light. For reconstitution, most researchers use Bacteriostatic Water, adding it slowly and swirling gently. Our guides to peptide reconstitution, how long peptides last and the peptide calculator cover the practical detail.

Related Compounds in the Growth Hormone Family

Ipamorelin and GHRP-2 have close neighbours on both sides of the growth hormone system.

GHRP-6

GHRP-6 is the third member of this trio, the original hexapeptide from Bowers’s work, known for a particularly strong appetite effect. Our comparison GHRP-2 vs GHRP-6 covers it in detail, and the GHRP-6 guide tells its story.

The GHRH analogues

On the other side of the system, Sermorelin, Tesamorelin and CJC-1295 with DAC act on the GHRH receptor rather than the ghrelin receptor. Because the two receptors use different signalling routes, GHRPs are frequently paired with GHRH analogues, most commonly in the CJC-1295 (No DAC) + Ipamorelin (Blend). See Tesamorelin vs Ipamorelin and the two-pathway approach.

Further down the axis

IGF-1 LR3 lets researchers study the downstream hormone directly. Our GHRP-2 research guide and GHRP-2’s story as a diagnostic drug go deeper into GHRP-2 on its own.

Browse the full group in our endocrine and hormonal research peptides category.

Ipamorelin and GHRP-2 Questions, Answered

Is GHRP-2 stronger than Ipamorelin?

In the original head-to-head research in pigs, GHRP-2 was more potent, needing less to trigger growth hormone release, although Ipamorelin reached a comparable or higher maximum response.

Why is Ipamorelin called selective?

Because in the 1998 comparison it released growth hormone without significantly raising ACTH or cortisol, unlike GHRP-2 and GHRP-6, and without affecting other pituitary hormones.

What is pralmorelin?

Pralmorelin is the drug name for GHRP-2. It is used in Japan as a diagnostic stimulation test for severe adult growth hormone deficiency.

Does GHRP-2 affect appetite?

Yes. A 2005 study in healthy men found that GHRP-2 infusion increased food intake at a buffet meal by 35.9%, mirroring the effect of ghrelin itself.

Is GHRP-2 the same as GHRP-6?

No. They are close relatives from the same research programme and act on the same receptor, but GHRP-2 is more potent at releasing growth hormone, while GHRP-6 has a stronger reputation for stimulating appetite. Both raised ACTH and cortisol in the original comparison with Ipamorelin.

How does Ipamorelin compare with Sermorelin?

They work on different receptors. Sermorelin is a GHRH analogue that acts on the GHRH receptor, the body’s main “go” signal for growth hormone. Ipamorelin acts on the ghrelin receptor, a separate route into the same pituitary cells. Because the two routes use different internal signalling, GHRH analogues and ghrelin receptor agonists are often studied together rather than as alternatives.

Why do both peptides use unusual amino acids?

Mainly for stability and fit. Mirror-image D-amino acids resist the enzymes that break down natural peptides, and bulky building blocks such as naphthylalanine help the molecules lock into the ghrelin receptor. Those same unusual features are why careful analytical testing of each batch matters so much.

Can Ipamorelin and GHRP-2 be studied together?

Because they share a receptor, combining them mostly adds more of the same signal. Their more useful pairing is as a comparison: studying each separately helps separate growth hormone effects from stress hormone and appetite effects.

Power or Precision? It Depends on the Question

GHRP-2 and Ipamorelin are two answers to the same challenge, set decades apart. GHRP-2 is the powerhouse: potent, reliable enough to become a diagnostic drug, and capable of reproducing ghrelin’s hunger signal in people. Ipamorelin is the precision tool: engineered to release growth hormone as cleanly as the body’s own GHRH, leaving the stress hormones alone.

Neither is simply better. Each is the right tool for a different kind of experiment, and together they make it possible to pull apart the many things the ghrelin receptor does. Explore Ipamorelin and GHRP-2 from Crown Peptides, every batch HPLC and mass spectrometry verified, dispatched from the UK.